These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 24406289

  • 1. Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests.
    Eller T, Busse J, Dittrich M, Flieder T, Alban S, Knabbe C, Birschmann I.
    Clin Chem Lab Med; 2014 Jun; 52(6):835-44. PubMed ID: 24406289
    [Abstract] [Full Text] [Related]

  • 2. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
    Wong PC, Jiang X.
    Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry.
    Adelmann D, Wiegele M, Wohlgemuth RK, Koch S, Frantal S, Quehenberger P, Scharbert G, Kozek-Langenecker S, Schaden E.
    Thromb Res; 2014 Oct; 134(4):918-23. PubMed ID: 25179518
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Pharmacodynamic and pharmacokinetic characteristics. Mechanism of action of the new oral anticoagulants].
    Roldán Schilling V, Vicente García V.
    Med Clin (Barc); 2012 Oct; 139 Suppl 2():10-2. PubMed ID: 23498066
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Advantages and limitations of the new anticoagulants.
    Schulman S.
    J Intern Med; 2014 Jan; 275(1):1-11. PubMed ID: 24112453
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
    Mani H, Herth N, Kasper A, Wendt T, Schuettfort G, Weil Y, Pfeilschifter W, Linnemann B, Herrmann E, Lindhoff-Last E.
    Ther Drug Monit; 2014 Oct; 36(5):624-31. PubMed ID: 24577124
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Laboratory testing for the new oral anticoagulants: a review of current practice.
    Favaloro EJ, Bonar R, Butler J, Marsden K.
    Pathology; 2013 Jun; 45(4):435-7. PubMed ID: 23635821
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.
    Bonar R, Favaloro EJ, Mohammed S, Ahuja M, Pasalic L, Sioufi J, Marsden K.
    Pathology; 2016 Jan; 48(1):60-71. PubMed ID: 27020211
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.